Clinical trials: Dementia Alzheimers
Late Onset Alzheimer Disease
Response to Donepezil, Drug Plasma Concentration and the CYP2D6 and APOE Genetic Polymorphisms
Pharmacological treatment of AD is currently based on cholinesterase inhibitors (ChEI) and memantine, which have been shown to lead to modest, although effective, clinical benefits.
- Trial name
- NCT03349320
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Alzheimer Disease, Intestinal Microbiota
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
The objective of the study is to highlight a modification of the composition of the intestinal microbiota associated with the diagnosis of Alzheimer's disease and its most unfavorable form, Rapid Cognitive Decline (DCR).
- Trial name
- MiDCR (NCT03487380)
- Testing
- Fecal sample collection
- Where
- 2 sites in France
- Volunteers
- 86 people
- Sponsor
- Nantes University Hospital
Alzheimer Disease
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
This is a phase 2, open-label, multiple-center, non-randomized single dose study to assess the safety and efficacy of [18F]NAV4694 PET imaging in detecting beta-amyloid plaque in the brain in subjects with probable AD compared…
- Trial name
- NCT01680588
- Testing
- [18F]NAV4694
- Where
- 7 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Navidea Biopharmaceuticals
Alzheimer´s Disease
Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid
The study is carried out in order to investigate if [11C]AZD2995, compared to [11C]AZD2184, is a more suitable PET ligand for in vivo imaging of β amyloid depositions in the human brain.
- Trial name
- PET (NCT00692705)
- Testing
- Radioligand (11C)AZD2995, Radioligand (11C)AZD2184
- Where
- Sweden
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer Disease, Magnetic Resonance Spectroscopy
New Imaging Biomarkers Predictive of MA Progression
The pathophysiology of AD is complex. In addition to amyloid plaques and neurofibrillary degeneration, there is a metabolic alteration of the energy pathways, oxidative phosphorylation and glycolysis, which are involved in brain…
- Conditions
- Alzheimer Disease, Magnetic Resonance Spectroscopy, Ultra High Field 7T, Progression of Disease
- Trial name
- MR7T-PRADA (NCT05939362)
- Testing
- MRI follow-up
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Poitiers University Hospital
Gestational Diabetes Mellitus
A Mobile Smartphone Application to Promote a Healthy Diet and Physical Activity Among Pregnant Women With GDM - RCT
In this study, the investigators will test a new way to communicate advice on diet and lifestyle to women with gestational diabetes mellitus by app downloaded on women's smartphone.
- Trial name
- NCT02588729
- Testing
- Pregnant+ app for smartphone
- Where
- Norway
- Volunteers
- 238 people
- Sponsor
- Oslo Metropolitan University
Alzheimer's Disease
A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study
The purpose of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00809510
- Testing
- ABT-089
- Where
- 22 sites in United States
- Volunteers
- 63 people
- Sponsor
- Abbott
Alzheimer Disease, Mild Cognitive Impairment
Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease
This study investigates the effects of Valaciclovir treatment to individuals with Alzheimer's disease or Mild Cognitive Impairment of Alzheimer's Disease Type.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Herpes Simplex
- Trial name
- VALZ-Pilot (NCT02997982)
- Testing
- Valaciclovir 500Mg Tablet
- Where
- 2 sites in Sweden
- Volunteers
- 33 people
- Sponsor
- Hugo Lovheim
Mild Cognitive Impairment, Dementia
A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
The purpose of this study is to determine whether treatment with the investigational drug ladostigil will delay the onset of Alzheimer's disease(AD) in patients with Mild Cognitive Impairment (MCI).
- Trial name
- NCT01429623
- Testing
- ladostigil hemitartrate
- Where
- 12 sites in Austria, Germany and 1 more
- Volunteers
- 210 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Cognitive Dysfunction, Alzheimer Disease
ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain vascular health in older adults…
- Conditions
- Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of
- Trial name
- NCT07392723
- Testing
- Alpha-Linolenic Acid (2.6 g/day)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Michal Schnaider Beeri, Ph.D.
Alzheimer Disease
A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients
A 10-week safety and tolerability study of a potential treatment for mild to moderate Alzheimer's disease.
- Trial name
- NCT00141661
- Testing
- PF-04494700 - Low Dose Arm, PF-04494700 - High Dose Arm
- Where
- 12 sites in United States
- Volunteers
- 67 people
- Sponsor
- Pfizer
Alzheimer's Disease
Bexarotene Amyloid Treatment for Alzheimer's Disease
Retinoid X receptors (RXR) are nuclear receptors that have been linked to numerous metabolic pathways relevant to Alzheimer's disease (AD) and Aβ (harmful protein) production and removal.
- Trial name
- BEAT-AD (NCT01782742)
- Testing
- Bexarotene
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Cleveland Clinic
Alzheimer Disease
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the safety and tolerability of NSC001 on in patients with mild to moderate Alzheimer's disease and to evaluate the influence of the compound on cognitive function.
- Trial name
- NCT06995573
- Testing
- NSC001
- Where
- 10 sites in Austria, Germany
- Volunteers
- 90 people
- Sponsor
- NSC-Therapeutics
Alzheimer's Disease
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
This is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects with…
- Trial name
- NCT02580305
- Testing
- SUVN-502, Donepezil, Memantine
- Where
- 71 sites in United States
- Volunteers
- 564 people
- Sponsor
- Suven Life Sciences Limited
Cognition Disorders
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
The LEARN study a multicenter, observational study will that will evaluate the rate of cognitive change in approximately 500 clinically normal older individuals who "screen-fail" for the A4 trial on the basis of their screening…
- Trial name
- LEARN (NCT02488720)
- Where
- 40 sites in United States
- Volunteers
- 538 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Alzheimer Disease, Down Syndrome
Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the safety and tolerability of ION269 in adults with Down syndrome with evidence of brain amyloid positivity.
- Trial name
- NCT06673069
- Testing
- ION269
- Where
- 6 sites in United States, Spain
- Volunteers
- 1 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Parkinson Disease, Alzheimer Disease
Autoimmune Features of Neurodegenerative Disorders
This study is being conducted to better understand the role of inflammation in Parkinson's disease (PD) and Alzheimer's disease (AD).
- Conditions
- Parkinson Disease, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- NCT04239079
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Columbia University
Parkinson Disease, Alzheimer Disease
Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population
A two months intervention in which two groups of cognitive disorders, Parkinson and Alzheimer's disease, will receive 50g/day of a commercial MCT supplement combined with supervised aerobic exercise 3 times/week.
- Trial name
- PARKA (NCT04322461)
- Testing
- Betaquik MCT supplement
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Université de Sherbrooke
Aging and Exercise Impacts on Glymphatic Function
Aging and Exercise Impacts on Glymphatic Function
This is a prospective, interventional, non-blinded, single center research project that will recruit cognitively unimpaired subjects in the 25-55 year old and 55-75 year old range.
- Trial name
- NCT07775196
- Testing
- Acute Aerobic exercise
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Alzheimer's Disease
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
This study aims to compare the effects of RO7568282 versus a placebo in people in the early stages of Alzheimer's disease (AD).
- Trial name
- TARBELA-AD (NCT07781657)
- Testing
- RO7568282
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.